Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of Macrophage Migration Inhibitory Factor (MIF) with Therapy Response and Clinical Outcomes in HPV-Related Head and Neck Squamous Cell Carcinoma: A Preliminary Report.

Current oncology (Toronto, Ont.)·2026
Same author

BATF2 is a glutamine-responsive tumour suppressor required for type-I interferon-dependent anti-tumour immunity.

Nature communications·2025
Same author

Radiation-Induced Skin Injury: Mechanisms, Clinical Manifestations, and Management.

International journal of dermatology·2025
Same author

Tropisetron Suppresses Chronic Pancreatitis and Pancreatic Cancer by Blocking Interleukin 33 Expression.

Cancers·2025
Same author

Hepatitis B virus promotes liver cancer by modulating the immune response to environmental carcinogens.

Nature communications·2025
Same author

Long-term mortality outcomes among immunotherapy recipients treated with dupilumab for the management of cutaneous immune-related adverse events.

Journal for immunotherapy of cancer·2025
Same journal

The Impact of Relative Dose Intensity on pCR in Neoadjuvant Chemotherapy of Muscle-Invasive Urothelial Cancer: a Multicentre Retrospective Study.

The oncologist·2026
Same journal

Prevalence, treatment and survival of Malignant Peripheral Nerve Sheath Tumor in the Danish neurofibromatosis type 1 population.

The oncologist·2026
Same journal

Molecular Tumor Board-Guided Osimertinib Therapy in EGFR L858R/Q701L-Mutant Lung Adenocarcinoma Supported by Functional Validation.

The oncologist·2026
Same journal

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
Same journal

Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.

The oncologist·2026
Same journal

Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 Framework.

The oncologist·2026
See all related articles

Related Experiment Video

Updated: Sep 4, 2025

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.0K

Lethal Dermal Sarcoma in Immunosuppressed Patients.

Marjan Azin1,2,3, Amir H Ameri1,2,3, Ruth K Foreman4

  • 1Cutaneous Biology Research Center, Department of Dermatology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

The Oncologist
|July 22, 2022
PubMed
Summary
This summary is machine-generated.

Organ transplant recipients (OTRs) face increased skin cancer risk. Pleomorphic dermal sarcoma is a rare, aggressive cancer causing significant mortality in OTRs, highlighting the need for vigilant monitoring.

Keywords:
dermal sarcomaimmunosuppressionorgan transplant recipient

More Related Videos

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

12.9K
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

8.9K

Related Experiment Videos

Last Updated: Sep 4, 2025

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.0K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

12.9K
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells
08:52

Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells

Published on: June 13, 2018

8.9K

Area of Science:

  • Oncology
  • Dermatology
  • Transplantation Medicine

Background:

  • Skin cancer is the most common malignancy in organ transplant recipients (OTRs).
  • The incidence of skin cancer in OTRs is rising due to increased survival rates.
  • Immunosuppression is a significant risk factor for various cancers in OTRs.

Purpose of the Study:

  • To investigate the incidence and outcomes of pleomorphic dermal sarcoma in organ transplant recipients.
  • To analyze the relationship between immunosuppressive therapy and dermal sarcoma development.
  • To assess the mortality associated with dermal sarcoma in a high-risk skin cancer patient cohort.

Main Methods:

  • A single-center case series was conducted.
  • Data from over 200 patients at Massachusetts General Hospital High Risk Skin Cancer Clinics were reviewed over 3 years.
  • Focus was on patients diagnosed with scalp pleomorphic dermal sarcoma, particularly those with a history of keratinocyte carcinomas.

Main Results:

  • Pleomorphic dermal sarcoma was identified as a cause of skin cancer-related mortality in OTRs.
  • Three out of four patients with scalp dermal sarcoma were OTRs on immunosuppressants for a median of 9 years.
  • All recorded skin cancer-related deaths (2/2) in the cohort were attributed to metastatic dermal sarcoma.

Conclusions:

  • Pleomorphic dermal sarcoma is a significant contributor to skin cancer morbidity and mortality in organ transplant recipients.
  • Early detection and management of dermal sarcoma are crucial for improving outcomes in immunosuppressed individuals.
  • Further research is warranted to understand the pathogenesis and optimize treatment strategies for dermal sarcoma in OTRs.